1010 Sherbrooke St. West, Suite 408
11 articles with DalCor
12/10/2018Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
Researchers at the Montreal Heart Institute announced today that they have discovered the mechanism for the protective effects of reduced activity of the ADCY9 gene in atherosclerosis resulting from accumulation of fat in the artery walls.
Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.
DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients.
Dr. Laghrissi-Thode is Vice-President at Astra.
DalCor Announces Opening Of International Trial Sites For Its Dal-Gene Phase 3 Cardiovascular Outcomes Trial
DalCor's Dalcetrapib Demonstrates Genotype-Dependent Effects On Cholesterol Efflux And Inflammation In Data Published By The Montreal Heart Institute In Circulation: Cardiovascular Genetics